CELLDEX THERAPEUTICS INC (CLDX)
Health Care · biotechnology · NASDAQ
Celldex Therapeutics is a clinical-stage biotechnology firm developing novel monoclonal antibodies and antibody-drug conjugates to treat complex inflammatory and oncology diseases.
What CELLDEX THERAPEUTICS INC does
Celldex Therapeutics is a clinical-stage biotechnology company focused on the development of monoclonal antibodies and antibody-drug conjugates for the treatment of diseases related to inflammation and oncology. The company's pipeline centers on proprietary platform technologies designed to target immune pathways and cell-surface receptors. Its clinical programs address significant unmet medical needs through protein-based therapeutics.
Themes: oncology, inflammatory diseases, biotech R&D
Fundamentals
- Price$29.30 as of 2026-10-08 close
- Market cap$2.3B as of 2026-07-29 (share count; price 2026-10-08)
- 1-year return+7.6% 2025-10-08 close $27.24 → 2026-10-08 close $29.30
- P/En/a negative earnings
- Net margin-16748.0% FY2025, SEC XBRL
- ROE-49.1% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)-97.3% as of 2026-09-03
- Revenue CAGR (3y)-13.1% SEC XBRL
- Beta1.14 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CLDX compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CLDX is not currently in any published Top 10 list. Its scores are below.
Top 10 score
26.2 #1364 of 1,379 scored · #148 of 151 in Health Care
Valuation 51st (price to book 3.2) and financial health 48th (debt to equity 0, free cash flow margin -13829.1%); weakest is profitability (2nd, operating margin -18599.8%, return on equity -49.1%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How CELLDEX THERAPEUTICS INC looks technically
CELLDEX THERAPEUTICS INC (CLDX) is trading 9.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 278 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 27, in oversold territory (below 30). It just made a new 20-day low, its first since 2026-06-08, breaking below its recent trading range. It is 35.1% below its highest point of the past year. Trading volume is running unusually high — about 2.4× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 9.5% below its 200-day average, the long-term trend line — a long-term downtrend | -9.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $37.87 | $37.87 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $32.36 | $32.36 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 36.84. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 278 trading days ago — a "golden cross", a bullish long-term signal | 278 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 20.5 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 27, in oversold territory (below 30) | 27.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($28.64 to $41.62) — its "stochastic" reading is 5 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 5.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 36 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $45.14 | $45.14 |
|---|---|---|
| From the 52-week high | it is 35.1% below its 52-week high (its highest price of the past year) | -35.1% |
| Above the 52-week low | it is 32.6% above its 52-week low (its lowest price of the past year) | +32.6% |
| Below the 52-week high | it is 35.1% below its highest point of the past year | 35.1% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-08, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-06-08, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $579.70 (set on 2013-10-02) | $579.70 |
| Given back of the 52-week move | over the past year its closes ranged ($22.58 to $44.87), and it has given back well over two thirds of its rise from last year’s low — 70% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $30.38 to $31.09. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 69.8% |
| From the all-time high | it is 94.9% below its all-time high | -95.0% |
| Nearest price level | it is sitting right on a support level at $29.24 — a price it turned at three times since 2024-10-28, most recently on 2026-05-19. Since 2024-10-08 it has 11 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.2% |
| All-time low | its lowest closing price on record is $1.50 (set on 2020-03-19) | $1.50 |
| Above the all-time low | it is 1853.3% above its all-time low | +1,853% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months) | 98th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.75 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.75 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $27.17 and $40.67 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $27.17 – $33.92 – $40.67 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 1.8 daily ranges below its 200-day average price (9.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.4× its 30-day average, a sign of heightened interest | 2.35× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.2% |
|---|---|---|
| Gap filled | a 3.4% gap down opened on 2026-09-22 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -10.1% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 26.1 percentage points (the stock lost 25.1% while the market gained 1.0%) | -26.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 28.6 percentage points (the stock lost 24.8% while the market gained 3.8%) | -28.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 24.1 percentage points (the stock lost 6.6% while the market gained 17.5%) | -24.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 7.4 percentage points (the stock gained 7.6% while the market gained 15.0%) | -7.4% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 5.3% of the share price. | -24.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 11% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $32.87 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -10.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 17% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $35.23 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -16.8% |
Price levels it has turned at before
CLDX last closed at $29.30 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $29.24 | Support | 0.2% below the last close | turned there three times · 2024-10-28 to 2026-05-19 |
| $28.30 | Support | 3.4% below the last close | turned there 11 times · 2024-11-13 to 2026-06-08 |
| $30.44 | Resistance | 3.9% above the last close | turned there twice · 2025-12-08 to 2026-09-28 |
| $31.47 | Resistance | 7.4% above the last close | turned there twice · 2026-02-26 to 2026-04-29 |
| $32.14 | Resistance | 9.7% above the last close | turned there twice · 2026-03-10 to 2026-05-28 |
| $26.30 | Support | 10.3% below the last close | turned there twice · 2025-01-30 to 2025-09-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $36.84.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $33.03 and $36.00 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-10-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Unusually heavy trading volume · Broke down to a new 20-day low · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.27 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$63.07 range $28.00 – $100.00; median $64.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CLDX
- Consensus EPS estimate-$1.01 next reporting period, as of 2026-10-07
- Estimate change, 30 days-$0.00552 from -$1.01, on 2026-09-02, 35-day window
- Readings revised upward0% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has a history of losses, is currently unprofitable, and expects to incur significant losses for the foreseeable future as it continues its research and development efforts.","Success is dependent on the clinical development, regulatory approval, and commercialization of its product candidates, which carry a high risk of failure."]
What changed in the latest 10-Q
AI-assisted comparison of CLDX's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- In the newer filing (filed 2026-08-06), the CSU section states: 'Enrollment is complete in our Phase 3 studies in CSU and topline data will be available in September/October 2026.'
- In the newer filing (filed 2026-08-06), the text in the CSU bullet begins without the phrase 'In February 2026, we announced that' that appeared in the older filing.
- Removed:
- In the older filing (filed 2026-05-07), the CSU section stated: 'In February 2026, we announced that enrollment is complete in our Phase 3 studies in CSU and that topline data will be available in the fourth quarter of 2026.'
- Reworded:
- The timing for topline data changed from 'the fourth quarter of 2026' (older filing, filed 2026-05-07) to 'September/October 2026' (newer filing, filed 2026-08-06).
- The older filing's phrase 'In February 2026, we announced that enrollment is complete' was replaced in the newer filing with 'Enrollment is complete,' removing the announcement date reference.
- Notes:
- The provided MD&A excerpts in both filings appear to be truncated at the end (ending mid-sentence in the Cold Urticaria/Systemic Dermographism section), so changes beyond the point of truncation could not be assessed.
- Only differences within the provided excerpt text were compared; additional sections of the MD&A not included in the source texts are not addressed.
Risk Factors
- Added:
- Added exhibit 10.1: Amendment No. 4 to Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan, incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K, filed on June 26, 2026 with the Securities and Exchange Commission.
- Added footnote indicator '†' for exhibit 10.1, indicating a management contract or compensation plan, contract or arrangement.
- Added the line '† Indicates a management contract or compensation plan, contract or arrangement.'
- Reworded:
- Signature dates changed from May 7, 2026 (older filing) to August 6, 2026 (newer filing) for Anthony S. Marucci and Sam Martin.
- Notes:
- The extracted 'Risk Factors' section includes content from Items 5 and 6, the exhibit index, and signatures, not solely risk factor text. The risk factor disclosure itself appears unchanged between filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CLDX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CLDX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 14,741,645
- Reported value $548,536,611
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CLDX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CLDX had 8,953,127 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CLDX had 11.4% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.12 days to cover at the same settlement.
- Reported short interest (shares) 8,953,127
- Short interest (% of shares outstanding) 11.4%
- Prior settlement (shares) 8,641,597
- Reported change 3.61%
- Days to cover (reported) 13.12
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Regeneron Pharmaceuticals (REGN)
- Sanofi (SNY)
- Amgen (AMGN)
- Bristol-Myers Squibb (BMY)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CLDX vs…
CELLDEX THERAPEUTICS INC is found in…
Frequently asked questions
What does CELLDEX THERAPEUTICS INC (CLDX) do?
Celldex Therapeutics is a clinical-stage biotechnology company focused on the development of monoclonal antibodies and antibody-drug conjugates for the treatment of diseases related to inflammation and oncology. The company's pipeline centers on proprietary platform technologies designed to target immune pathways and cell-surface receptors. Its clinical programs address significant unmet medical needs through protein-based therapeutics.
What sector is CELLDEX THERAPEUTICS INC (CLDX) in?
CELLDEX THERAPEUTICS INC (CLDX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are CELLDEX THERAPEUTICS INC's (CLDX) competitors?
Notable peers of CELLDEX THERAPEUTICS INC (CLDX) include Regeneron Pharmaceuticals, Sanofi, Amgen, Bristol-Myers Squibb and Novartis. This peer set is informational only — not financial advice.
Is CELLDEX THERAPEUTICS INC (CLDX) overbought or oversold right now?
CELLDEX THERAPEUTICS INC (CLDX) is currently in oversold territory (its 14-day RSI is 27, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CLDX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.